Confirming GLP-1 Peptide Identity and Structure

Building on the impurity landscape outlined in the previous episode, Sam Whitmarsh turns the conversation toward a more fundamental question: once an impurity or component is detected, how do analytical scientists confirm exactly what it is? Piotr Alvarez walks through his lab's standard identity-confirmation workflow, beginning with high-resolution mass spectrometry (HRMS) to establish an accurate molecular weight. That measurement alone, he cautions, cannot confirm whether the correct amino acid sequence is present, which is why the workflow typically advances to liquid chromatography (LC)–MS/MS analysis. Even that step has limits: collision-induced dissociation (CID), the standard fragmentation approach, cannot distinguish between certain isomeric amino acids, such as leucine and isoleucine. For those cases, the team turn to alternative fragmentation mechanisms like electron-capture dissociation (ECD). He also describes a complementary technique for cases requiring full amino acid analysis: hydrolyzing the peptide completely, then derivatizing and analyzing the individual amino acids using liquid chromatography with fluorescence detection.

Nitish Sharma describes a parallel workflow from his own laboratory, which similarly starts with direct mass analysis via HRMS, checking measured mass against theoretical mass within an acceptable ppm error. From there, amino acid sequencing is confirmed using either HRMS or dedicated peptide sequencing methods. Sharma adds a regulatory dimension often overlooked outside peptide-focused labs: confirming the D- or L-configuration of specific isomeric amino acids to demonstrate that no racemization occurred during synthesis—a requirement increasingly expected by regulators for peptide therapeutics.

Taken together, the two workflows illustrate that identity confirmation for GLP-1 peptides is rarely a single test, but a layered combination of mass accuracy, sequence confirmation, and stereochemical verification.